Autologous Fecal Therapy
Infectious Disease of Digestive Tract
Bottom Line
View on ClinicalTrials.gov: NCT02046525 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Autologous fecal microbiota therapy (Biological); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Dec 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Restoration of Microbial Community Composition to the Pre-antibiotic State by 90 Days Post FMT or Saline Enema |
5; 5 | — |
Summary
Eligibility Criteria
Inclusion Criteria
Healthy Adults 18-70 years of age-
Exclusion Criteria
history of allergic reaction to beta-lactam antimicrobials; any non-topical antimicrobial exposure or tube feeds as a primary source of nutrition in the past six months; pregnant or risk of becoming pregnant during the study period; gastroenteritis in the last 3 months; incontinent of stool; prior resection or alteration of the stomach; small bowel, or colon; unwillingness to receive an enema/FMT; known colonization with an MDRO; anticipated change in diet or medications, or elective surgery, during the study period; or a history of an intestinal disorder -
Data sourced from ClinicalTrials.gov (NCT02046525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.